I am afraid I was similarly, not overly impressed by...

I am afraid I was similarly, not overly impressed by theprobability of potential commercial returns on GvHD for CYP to havespent much time in depth on it.


Theimportance of GvHD to both CYP and MSB (the mesenchymal stem cellbased cell therapy field really I think) is, in my opinion, that itson the very point of the regulatory (FDA) / commercial (can wholeM(edicinal) S(ignalling) cells be therapeutic products sold for aprofit?) interface.

SI speaks of a haloeffect – I wouldn’t use that language exactly but I think I agreewith him on the ramifications for MSB and by extension for the MSCfield. But big failure as well as big success is possible at thismoment, in my opinion too. It's down to can the totality of the datapossibly amount to a totality that's enough, in my opinion. With theball firmly in the FDA's court.

Inmy opinion none of the potentially more commercial indications (likeOA) look particularly real (commercial scale - not merely clinicaltrial scale -manufacturing needs to be demonstrated for OA, HeartDisease, asthma etc (potentially large commercial markets) as well)until the FDA/CBER grants approval in something first -doesn't really matter what, to someone, its just that GvHD(MSB's currently) happens to be the closest MSB having done a phase 3in GvHD.